Outcomes of patients with HBV reactivation.
| Anti-HBs at Baseline, mIU/l | Immunosuppressive Regimen | Time to Detection of HBV, Weeks | Outcome | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Age/Sex | Diagnosis | PSL, mg | Steroid Pulse | Immunosuppressant | Biologics | AST/ALT Elevation | HBsAg | HBeAg | |||
| 1 | 77 F | RA + IP | 168.5 | 60 | + | TAC | – | 4 | – | – | – | Recovered with NAA |
| 2 | 78 F | MPA | 5.31 | 40 | – | IVCY | – | 8 | – | – | – | Recovered without NAA |
| 3 | 58 F | SLE | 0.24 | 60 | + | IVCY + TAC | – | 4 | – | + | + | Died due to sepsis |
| 4 | 71 F | RA + EBV-LPD | 0.28 | 10 | – | – | RTX | 4 | – | – | – | Recovered without NAA |
| 5 | 30 F | SLE | 0.35 | 60 | + | IVCY | – | 8 | + | – | – | Died due to sepsis |
| 6 | 59 F | SLE | 47.86 | 60 | + | IVCY | – | 4 | – | + | – | Died due to hemolytic anemia |
RA: rheumatoid arthritis; IP: interstitial pneumonia; MPA: microscopic polyangiitis; SLE: systemic lupus erythematosus; EBV-LPD: Epstein-Barr virus-related lymphoproliferative disease; PSL: prednisolone; TAC: tacrolimus; IVCY: intravenous cyclophosphamide; RTX: rituximab; NAA: nucleic acid analog; AST: aspartate aminotransferase; ALT: alanine aminotransferase.